Category Archives: Clinical Accelerator

Temple Therapeutics BV Announces Publication of Key Mechanism Data for Evitar™

Below, we are re-publishing with permission the press-release issued by Temple Therapeutics BV on the 10th of September 2018 Supports Evitar’s™ Novel Approach for Preventing Acute Tissue Fibrosis (Surgical Adhesions) Geleen, The Netherlands Temple Therapeutics BV (the “Company” or “Temple”)- September … Continue reading

Posted in Biotech, Clinical Accelerator | Leave a comment

Clinical Accelerator announces collaboration with Oncolix for developing Prolanta™, a targeted therapeutic protein for the treatment of ovarian, breast and other cancers

Clinical Accelerator, a full-service contract research organization, is pleased to announce that it has entered into a collaboration with Oncolix, for conducting clinical studies for its analogue protein, Prolanta, to treat ovarian cancer. The trials will be conducted in the … Continue reading

Posted in Biotech, Central and Eastern Europe, Clinical Accelerator | Leave a comment

VisCardia Announces First Implant of the VisONE® System for Treating Heart Failure

Below, we are re-publishing with permission the press-release issued by VisCardia Inc. on the 1st of August 2018 PORTLAND, Ore.–VisCardia Inc., a privately held medical device developer, announced today the first implant of the VisONE® implantable system for heart failure, and … Continue reading

Posted in Central and Eastern Europe, Clinical Accelerator | Leave a comment

FDA inspections produce solid evidence of high quality clinical trial data originating in Central and Eastern Europe

Clinical Accelerator is a clinical CRO with a special focus on Central and Eastern Europe currently operating in 11 countries of that region: Bulgaria, Estonia, Georgia, Hungary, Latvia, Lithuania, Moldova, Poland, Romania, Russian Federation, and the Ukraine (listed alphabetically). The … Continue reading

Posted in Central and Eastern Europe, ClinAccel.Net, Clinical Accelerator, FDA | Leave a comment

ARREST Phase IIb Top-Line 52 weeks results

Below, we are re-publishing with permission the press-release issued by Galmed Pharmaceuticals Ltd. on the 12th of June 2018 Galmed’s 600 mg Aramchol™ Achieved a Regulatory Approvable Endpoint Showing NASH Resolution Without Worsening of Fibrosis, in NASH Patients, in the Global … Continue reading

Posted in Central and Eastern Europe, ClinAccel.Net, Clinical Accelerator | Leave a comment

Replicor discloses long term functional control of HBV and HDV infection in high proportions of treated patients at EASL 2018

Below, we are re-publishing with permission the press-release issued by Replicor on the 13th of April 2018 MONTREAL, April 13, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic … Continue reading

Posted in Central and Eastern Europe, ClinAccel.Net, Clinical Accelerator, Conferences | Leave a comment

ValiSeek – ValiRx unveils positive results from VAL401 Phase II lung cancer trial

Below, we are re-publishing the news issued by ValiSeek on the 12th of December 2017 ValiSeek – Clinical Development Update on VAL401 Dr Suzy Dilly, CEO of ValiSeek provides a positive update on the clinical progress of VAL401, the anti-cancer compound. … Continue reading

Posted in Clinical Accelerator | Leave a comment